ZTS Quote, Financials, Valuation and Earnings

Merck & has a net margin of 25.08% compared to Zoetis's net margin of 23.96%. Zoetis's return on equity of 49.71% beat Merck &'s return on equity of 40.25%.

Zoetis has a consensus price target of $199.99, signalling upside risk potential of 22.83%. On the other hand Merck & has an analysts' consensus of $112.07 which suggests that it could grow by 27.93%. Given that Merck & has higher upside potential than Zoetis, analysts believe Merck & is more attractive than Zoetis.

Zoetis has a beta of 0.941, which suggesting that the stock is 5.862% less volatile than S&P 500. In comparison Merck & has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.24%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.1%. Merck & offers a yield of 3.61% to investors and pays a quarterly dividend of $0.81 per share. Zoetis pays 31.62% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.3B, which are smaller than Merck & quarterly revenues of $15.6B. Zoetis's net income of $581M is lower than Merck &'s net income of $3.7B. Notably, Zoetis's price-to-earnings ratio is 29.77x while Merck &'s PE ratio is 13.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.00x versus 3.47x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 25.08% compared to Zoetis's net margin of 2.31%. Zoetis's return on equity of 49.71% beat Pfizer's return on equity of 8.91%.

Zoetis has a consensus price target of $199.99, signalling upside risk potential of 22.83%. On the other hand Pfizer has an analysts' consensus of $31.26 which suggests that it could grow by 24.98%. Given that Pfizer has higher upside potential than Zoetis, analysts believe Pfizer is more attractive than Zoetis.

Zoetis has a beta of 0.941, which suggesting that the stock is 5.862% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.1%. Pfizer offers a yield of 6.76% to investors and pays a quarterly dividend of $0.43 per share. Zoetis pays 31.62% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Zoetis quarterly revenues are $2.3B, which are smaller than Pfizer quarterly revenues of $17.8B. Zoetis's net income of $581M is higher than Pfizer's net income of $410M. Notably, Zoetis's price-to-earnings ratio is 29.77x while Pfizer's PE ratio is 17.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.00x versus 2.24x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals has a net margin of 25.08% compared to Zoetis's net margin of 8.8%. Zoetis's return on equity of 49.71% beat Supernus Pharmaceuticals's return on equity of 7.61%.

Zoetis has a consensus price target of $199.99, signalling upside risk potential of 22.83%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $38.80 which suggests that it could grow by 19.68%. Given that Zoetis has higher upside potential than Supernus Pharmaceuticals, analysts believe Zoetis is more attractive than Supernus Pharmaceuticals.

Zoetis has a beta of 0.941, which suggesting that the stock is 5.862% less volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.835, suggesting its less volatile than the S&P 500 by 16.47%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.1%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 31.62% of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.3B, which are larger than Supernus Pharmaceuticals quarterly revenues of $174.2M. Zoetis's net income of $581M is higher than Supernus Pharmaceuticals's net income of $15.3M. Notably, Zoetis's price-to-earnings ratio is 29.77x while Supernus Pharmaceuticals's PE ratio is 24.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.00x versus 2.74x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services has a net margin of 25.08% compared to Zoetis's net margin of 17.38%. Zoetis's return on equity of 49.71% beat West Pharmaceutical Services's return on equity of 18.15%.

Zoetis has a consensus price target of $199.99, signalling upside risk potential of 22.83%. On the other hand West Pharmaceutical Services has an analysts' consensus of $285.01 which suggests that it could grow by 26.72%. Given that West Pharmaceutical Services has higher upside potential than Zoetis, analysts believe West Pharmaceutical Services is more attractive than Zoetis.

Zoetis has a beta of 0.941, which suggesting that the stock is 5.862% less volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.088, suggesting its more volatile than the S&P 500 by 8.847%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.1%. West Pharmaceutical Services offers a yield of 0.37% to investors and pays a quarterly dividend of $0.21 per share. Zoetis pays 31.62% of its earnings as a dividend. West Pharmaceutical Services pays out 12% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.3B, which are larger than West Pharmaceutical Services quarterly revenues of $748.8M. Zoetis's net income of $581M is higher than West Pharmaceutical Services's net income of $130.1M. Notably, Zoetis's price-to-earnings ratio is 29.77x while West Pharmaceutical Services's PE ratio is 33.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.00x versus 5.73x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.